1. Home
  2. XP vs GKOS Comparison

XP vs GKOS Comparison

Compare XP & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XP Inc.

XP

XP Inc.

N/A

Current Price

$13.12

Market Cap

10.2B

Sector

Finance

ML Signal

N/A

Logo Glaukos Corporation

GKOS

Glaukos Corporation

N/A

Current Price

$237.72

Market Cap

14.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
XP
GKOS
Founded
2001
1998
Country
Cayman Islands
United States
Employees
N/A
1094
Industry
Investment Bankers/Brokers/Service
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.2B
14.0B
IPO Year
2019
2015

Fundamental Metrics

Financial Performance
Metric
XP
GKOS
Price
$13.12
$237.72
Analyst Decision
Buy
Strong Buy
Analyst Count
12
13
Target Price
$19.94
★ $243.85
AVG Volume (30 Days)
★ 17.8M
1.5M
Earning Date
11-16-2026
10-28-2026
Dividend Yield
★ 4.83%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $507,442,000.00
Revenue This Year
$12.83
$53.82
Revenue Next Year
$11.88
$28.56
P/E Ratio
$11.42
★ N/A
Revenue Growth
N/A
★ 32.33
52 Week Low
$13.48
$93.96
52 Week High
$32.73
$255.19

Technical Indicators

Market Signals
Indicator
XP
GKOS
Relative Strength Index (RSI) 29.48 60.24
Support Level N/A $147.72
Resistance Level $17.12 $255.19
Average True Range (ATR) 0.63 11.87
MACD 0.03 -1.86
Stochastic Oscillator 4.34 48.42

Price Performance

Historical Comparison
XP
GKOS

About XP XP Inc.

XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission. Geographically, the company derives maximum revenue from Brazil and also has its presence in other countries.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: